This clinical trial studies the use of vormatrigine (also known as PRAX-628) in adults who have epilepsy with either focal onset seizures or primary generalized tonic-clonic seizures. These types of seizures are different forms of epilepsy where electrical disturbances in the brain cause sudden, uncontrolled movements or changes in behavior.
The study aims to determine how safe and well-tolerated vormatrigine is when given to patients who have previously received this medication in other studies or through special access programs. The medication comes in the form of capsules that are taken by mouth. The treatment period may last up to 24 months.
During the study, doctors will monitor patients’ health through various tests and check how well the medication is working to control seizures. They will pay special attention to any side effects that might occur during treatment and measure the amount of medication in patients’ blood. The study will also track changes in the severity of the condition as observed by both doctors and patients.
Germany 
Italy 
Poland 
Spain 
